Cambridge Biomedical is pleased to collaborate with XenTech, a patient-derived tumor xenograft platform. Extending our offerings from target discovery through to phase three clinical trials.


Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

XenTech Company Information

Xentech Publications

Xentech Home Page


For more information please click here to contact us 

All rights reserved. Cambridge Biomedical, the Cambridge Biomedical logo, Science and Service, and Custom
Solutions for Life Sciences Companies are registered or unregistered trademarks of Cambridge Biomedical Inc.
|     Privacy Statement     | Terms of Use